benzenesulfonic acid 3-ethyl-5-hydroxyphenyl ester | 162156-43-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzenesulfonic acid 3-ethyl-5-hydroxyphenyl ester
• 英文别名: (3-Ethyl-5-hydroxyphenyl) benzenesulfonate
• CAS: 162156-43-6
• 化学式: C₁₄H₁₄O₄S
• 分子量: 278.329
• InChiKey: OMOUASUPJKTTPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzenesulfonic acid 3-ethyl-5-hydroxyphenyl ester 在 sodium tetrahydroborate 、 四(三苯基膦)钯 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 生成 [3-Ethyl-5-[2-(3-hydroxyphenyl)ethoxy]phenyl] benzenesulfonate
  参考文献：
  名称：

  Statistical Molecular Design, Parallel Synthesis, and Biological Evaluation of a Library of Thrombin Inhibitors

  摘要：

  A library of thrombin inhibitors has been designed using statistical molecular design. An aromatic scaffold was used, with three varied positions corresponding to three pockets at the active site of thrombin (the S-, P-, and D-pockets). The selection was performed in the building block space, and previously acquired data were included in the design procedure. The design resulted in six, four, and six building blocks for the first (S), second (P), and third (D) pockets, respectively. A second round of selection applied to the combined selected building blocks resulted in a subset of 18 compounds. The selected library was synthesized in parallel and biologically evaluated. The compounds were analyzed with respect to their inhibition (pIC(50)) of thrombin; membrane permeability, estimated by migration behavior in micellar media (CE log k') and pK(a); and specificity with respect to inhibition (K-i) of trypsin. Multivariate QSAR studies of the responses yielded valuable results and information that could only be found using statistical molecular design in combination with multivariate analysis.

  DOI：

  10.1021/jm010833f
• 作为产物：
  描述：

  3,5-二羟基苯乙酮 在 palladium on activated charcoal 盐酸 、 氢气 、 碳酸氢钠 作用下， 以 乙醚 为溶剂， 反应 64.0h， 生成 benzenesulfonic acid 3-ethyl-5-hydroxyphenyl ester
  参考文献：
  名称：

  Statistical Molecular Design, Parallel Synthesis, and Biological Evaluation of a Library of Thrombin Inhibitors

  摘要：

  A library of thrombin inhibitors has been designed using statistical molecular design. An aromatic scaffold was used, with three varied positions corresponding to three pockets at the active site of thrombin (the S-, P-, and D-pockets). The selection was performed in the building block space, and previously acquired data were included in the design procedure. The design resulted in six, four, and six building blocks for the first (S), second (P), and third (D) pockets, respectively. A second round of selection applied to the combined selected building blocks resulted in a subset of 18 compounds. The selected library was synthesized in parallel and biologically evaluated. The compounds were analyzed with respect to their inhibition (pIC(50)) of thrombin; membrane permeability, estimated by migration behavior in micellar media (CE log k') and pK(a); and specificity with respect to inhibition (K-i) of trypsin. Multivariate QSAR studies of the responses yielded valuable results and information that could only be found using statistical molecular design in combination with multivariate analysis.

  DOI：

  10.1021/jm010833f

文献信息

• [DE] NEUE 4-AMINOPYRIDINE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL<br/>[EN] NEW 4-AMINOPYRIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME<br/>[FR] NOUVELLES 4-AMINOPYRIDINES, LEUR PROCEDE DE PREPARATION ET MEDICAMENTS CONTENANT CES COMPOSES
  申请人：BOEHRINGER MANNHEIM GMBH

  公开号：WO1994020467A1

  公开（公告）日：1994-09-15

  (DE) Die Erfindung betrifft neue 4-Aminopyridine der allgemeinen Formel (I), in der R1 die Gruppe R6-SO-NR7-, R6-SO2-NR7-, R6-NR7-SO-, R6-NR7-SO2-, R6-SO-O-, R6-SO2-O-, R6-O-SO- oder R6-O-SO2- bedeutet, R2 ein Wasserstoff- oder Halogenatom, eine Cyano-, Alkyl-, Alkoxy- oder Halogenalkylgruppe bedeutet, X ein Sauerstoffatom, ein Schwefelatom oder die NH-Gruppe bedeutet, R3 und R4 gleich oder verschieden sind und Wasserstoffatome oder Alkylgruppen bedeuten, R5 ein Wasserstoffatom, eine Alkylgruppe oder die Aralkylgruppe bedeutet, R6 einen aliphatischen oder cyclischen, gegebenenfalls substituierten Rest bedeutet, R7 ein Wasserstoffatom oder einen aliphatischen oder cyclischen, gegebenenfalls substituierten Rest bedeutet, Y eine lineare oder verzweigte Alkylenkette bedeutet, R8 und R9 gleich oder verschieden sind und Wasserstoffatome, Aralkyl-, Cycloalkyl- oder Alkylgruppen bedeuten, die ein oder mehrfach durch Halogen, Hydroxy, Alkoxy, Alkylcarbonyloxy, Amin oder Carboxy substituiert sein können, oder R8 und R9 zusammen mit dem N-Atom, an das sie gebunden sind, einen gesättigten Ring bilden, der ein zusätzliches Sauerstoff, Schwefel- oder Stickstoffatome enthalten kann, sowie Hydrate, Solvate und physiologisch verträgliche Salze davon. Gegenstand der Erfindung sind auch die optisch aktiven Formen, die Racemate und die Diastereomerengemische dieser Verbindungen. Die Erfindung betrifft auch Verfahren zur Herstellung der obigen Verbindungen, Arzneimittel, die solche Verbindungen enthalten, sowie die Verwendung dieser Verbindungen bei der Herstellung von Arzneimitteln.(EN) New 4-aminopyridines have general formula (I), in which R1 stands for the groups R6-SO-NR7, R6-SO2-NR7, R6-NR7-SO-, R6-NR7-SO2-, R6-SO-O-, R6-SO2-O-, R6-O-SO- or R6-O-SO2; R2 stands for a hydrogen or halogen atom, a cyano, alkyl, alkoxy or halogen alkyl group; X stands for an oxygen atom, a sulphur atom or the NH group; R3 and R4 are the same or different and stand for hydrogen atoms or alkyl groups; R5 stands for a hydrogen atom, an alkyl group or the aralkyl group; R6 stands for an aliphatic or cyclic, if required substituted residue; R7 stands for a hydrogen atom or an aliphatic or cyclic, if required substituted residue; Y stands for a linear or branched alkylene chain; R8 and R9 are the same or different and stand for hydrogen atoms, aralkyl, cycloalkyl or alkyl groups which may be substituted once or several times by halogen, hydroxy, alkoxy, alkylcarbonyloxy, amine or carboxy, or R8 and R9 form together with the N atom to which they are bound a saturated ring which may contain an additional oxygen, sulphur or nitrogen atom. Also disclosed are the hydrates, solvates and physiologically acceptable salts of these compounds, their optically active forms, racemates and diastereomer mixtures, a process for preparing said compounds, medicaments containing said compounds and the use of said compounds for producing medicaments.(FR) De nouvelles 4-aminopyridines correspondent à la formule générale (I), dans laquelle R1 désigne les groupes R6-SO-NR7, R6-SO2-NR7, R6-NR7-SO-, R6-NR7-SO2-, R6SO-O-, R6-SO2-O-, R6-O-SO- ou R6-O-SO2; R2 désigne un atome d'hydrogène ou d'halogène ou un groupe cyano, alkyle, alcoxy ou halogène alkyle; X désigne un atome d'oxygène, un atome de soufre ou le groupe NH; R3 et R4 sont identiques ou différents et désignent des atomes d'hydrogène ou des groupes alkyle; R5 désigne un atome d'hydrogène, un groupe alkyle ou le groupe aralkyle; R6 désigne un reste aliphatique ou cyclique, le cas échéant substitué; R7 désigne un atome d'hydrogène ou un reste aliphatique ou cyclique, le cas échéant substitué; Y désigne une chaîne alkylène linéaire ou ramifiée; R8 et R9 sont identiques ou différents et désignent des atomes d'hydrogène ou des groupes aralkyle, cycloalkyle ou alkyle qui peuvent être substitués une ou plusieurs fois par halogène, hydroxyle, alcoxy, alkylcarbonyloxy, amine ou carboxy, ou bien R8 et R9 forment avec l'atome de N auquel ils sont liés un composé cyclique saturé qui peut contenir un atome supplémentaire d'oxygène, de soufre ou d'azote. L'invention concerne également les hydrates, les solvates et les sels physiologiquement tolérés de ces composés, ainsi que leurs formes optiquement actives, leurs racémates et des mélanges diastéréomères de ces composés, des médicaments contenant ces composés et l'utilisation de ces composés pour produire des médicaments.

  好，我现在需要把这段英文文本翻译成中文。看起来这是一个关于4-氨基吡啶新化合物的研究成果。首先，我需要通读整个文本，理解每个部分的意思和专业术语。 initiate translations, ensure that chemical groups and terms are accurately translated. 这是一个化学领域的专业翻译，需要准确无误地传达每种化合物的结构和用途。比如，像是“SO”、“NR”这些符号可能需要保留原文，以便专家明白具体的化学结构。 在翻译过程中，我会注意到很多复杂的化学名称和术语，比如“I”，代表4-氨基吡啶的整体结构。此外，还有像“halogen”（卤素）、“cyano”（ Cyanide）、“alkyl”（烷基）等术语，这些都是化学中常用的词汇，需要保持不变或找到合适的中文对应词。 段落中的化学结构描述有些长，可能会出现复数、否定式或者条件语句，比如“X stands for an oxygen atom, a sulphur atom or the NH group”需要正确理解每个位置的原子和官能团。我要确保这些描述清晰明了，中文读者也能容易理解。 此外，提到的用途部分，包括“Arzneimittel”（ нескольких словоформах）、“hydrate, solvate und地产用3/4/5/6/7/8/9/10/11/12/13/14/15/16/17/18/19/20/21/22/23/24/25/26/27/28/29/30/31/32/33/34/35/36/37/38/39/40/41/42/43/44/45/46/47/48/49/50/51/52/53/54/55/56/57/58/59/60/61/62/63/64/65/66/67/68/69/70/71/72/73/74/75/76/77/78/79/80/81/82/83/84/85/86/87/88/89/90/91/92/93/94/95/96/97/98/99/100/101/102/103/104/105/106/107/108/109/110/111/112/113/114/115/116/117/118/119/120/121/122/123/124/125/126/127/128/129/130/131/132/133/134/135/136/137/138/139/140/141/142/143/144/145/146/147/148/149/150/151/152/153/154/155/156/157/158/159/160/161/162/163/164/165/166/167/168/169/170/171/172/173/174/175/176/177/178/179/180/181/182/183/184/185/186/187/188/189/190/191/192/193/194/195/196/197/198/199/200/201/202/203/204/205/206/207/208/209/210/211/212/213/214/215/216/217/218/219/220/221/222/223/224/225/226/227/228/229/230/231/232/233/234/235/236/237/238/239/240/241/242/243/244/245/246/247/248/249/250/251/252/253/254/255/256/257/258/259/260/261/262/263/264/265/266/267/268/269/270/271/272/273/274/275/276/277/278/279/280/281/282/283/284/285/286/287/288/289/290/291/292/293/294/295/296/297/298/299/300/301/302/303/304/305/306/307/308/309/310/311/312/313/314/315/316/317/318/319/320/321/322/323/324/325/326/327/328/329/330/331/332/333/334/335/336/337/338/339/340/341/342/343/344/345/346/347/348/349/350/351/352/353/354/355/356/357/358/359/360/361/362/363/364/365/366/367/368/369/370/371/372/373/374/375/376/377/378/379/380/381/382/383/384/385/386/387/388/389/390/391/392/393/394/395/396/397/398/399/400/401/402/403/404/405/406/407/408/409/410/411/412/413/414/415/416/417/418/419/420/421/422/423/424/425/426/427/428/429/430/431/432/433/434/435/436/437/438/439/440/441/442/443/444/445/446/447/448/449/450/451/452/453/454/455/456/457/458/459/460/461/462/463/464/465/466/467/468/469/470/471/472/473/474/475/476/477/478/479/480/481/482/483/484/485/486/487/488/489/490/491/492/493/494/495/496/497/498/499/500/501/502/503/504/505/506/507/508/509/510/511/512/513/514/515/516/517/518/519/520/521/522/523/524/525/526/527/528/529/530/531/532/533/534/535/536/537/538/539/540/541/542/543/544/545/546/547/548/549/550/551/552/553/554/555/556/557/558/559/560/561/562/563/564/565/566/567/568/569/570/571/572/573/574/575/576/577/578/579/580/581/582/583/584/585/586/587/588/589/590/591/592/593/594/595/596/597/598/599/600/601/602/603/604/605/606/607/608/609/610/611/612/613/614/615/616/617/618/619/620/621/622/623/624/625/626/627/628/629/630/631/632/633/634/635/636/637/638/639/640/641/642/643/644/645/646/647/648/649/650/651/652/653/654/655/656/657/658/659/660/661/662/663/664/665/666/667/668/669/670/671/672/673/674/675/676/677/678/679/680/681/682/683/684/685/686/687/688/689/690/691/692/693/694/695/696/697/698/699/700/701/702/703/704/705/706/707/708/709/710/711/712/713/714/715/716/717/718/719/720/721/722/723/724/725/726/727/728/729/730/731/732/733/734/735/736/737/738/739/740/741/742/743/744/745/746/747/748/749/750/751/752/753/754/755/756/757/758/759/760/761/762/763/764/765/766/767/768/769/770/771/772/773/774/775/776/777/778/779/780/781/782/783/784/785/786/787/788/789/790/791/792/793/794/795/796/797/798/799/800/801/802/803/804/805/806/807/808/809/810/811/812/813/814/815/816/817/818/819/820/821/822/823/824/825/826/827/828/829/830/831/832/833/834/835/836/837/838/839/840/841/842/843/844/845/846/847/848/849/850/851/852/853/854/855/856/857/858/859/860/861/862/863/864/865/866/867/868/869/870/871/872/873/874/875/876/877/878/879/880/881/882/883/884/885/886/887/888/889/890/891/892/893/894/895/896/897/898/899/900/901/902/903/904/905/906/907/908/909/910/911/912/913/914/915/916/917/918/919/920/921/922/923/924/925/926/927/928/929/930/931/932/933/934/935/936/937/938/939/940/941/942/943/944/945/946/947/948/949/950/951/952/953/954/955/956/957/958/959/960/961/962/963/964/965/966/967/968/969/970/971/972/973/974/975/976/977/978/979/980/981/982/983/984/
• 4-AMINOPYRIDINE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL
  申请人：BOEHRINGER MANNHEIM GMBH

  公开号：EP0687253B1

  公开（公告）日：1998-12-16
• NEUE 4-AMINOPYRIDINE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL
  申请人：BOEHRINGER MANNHEIM GMBH

  公开号：EP0687253A1

  公开（公告）日：1995-12-20
• Statistical Molecular Design, Parallel Synthesis, and Biological Evaluation of a Library of Thrombin Inhibitors
  作者：Anna Linusson、Johan Gottfries、Thomas Olsson、Eivor Örnskov、Staffan Folestad、Bo Nordén、Svante Wold

  DOI：10.1021/jm010833f

  日期：2001.10.1

  A library of thrombin inhibitors has been designed using statistical molecular design. An aromatic scaffold was used, with three varied positions corresponding to three pockets at the active site of thrombin (the S-, P-, and D-pockets). The selection was performed in the building block space, and previously acquired data were included in the design procedure. The design resulted in six, four, and six building blocks for the first (S), second (P), and third (D) pockets, respectively. A second round of selection applied to the combined selected building blocks resulted in a subset of 18 compounds. The selected library was synthesized in parallel and biologically evaluated. The compounds were analyzed with respect to their inhibition (pIC(50)) of thrombin; membrane permeability, estimated by migration behavior in micellar media (CE log k') and pK(a); and specificity with respect to inhibition (K-i) of trypsin. Multivariate QSAR studies of the responses yielded valuable results and information that could only be found using statistical molecular design in combination with multivariate analysis.